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Abstract Preoperative diagnosis of hepatic angiomyolipoma is difficult, and the treatment for it remains controversial. The
aim of this study is to review our experience in the treatment of hepatic angiomyolipoma and to propose a treatment strategy
for this disease. We retrospectively collected the clinical, imaging, and pathological features of patients with hepatic
angiomyolipoma. Immunohistochemical studies with antibodies for HMB-45, actin, S-100, cytokeratin, vimentin, and c-kit
were performed. Treatment experience and long-term follow-up results are summarized. During a period of 9 years, 10
patients with hepatic angiomyolipoma were treated at our hospital. There was marked female predominance (nine patients).
Nine patients received surgical resection without complications. One patient received nonoperative management with
biopsy and follow-up. One patient died 11 months after surgery because of recurrent disease. We propose all symptomatic
patients should receive surgical resection for hepatic angiomyolipoma. Conservative management with close follow-up is
suggested in patients with asymptomatic tumors and meet the following criteria: (1) tumor size smaller than 5 cm, (2)
angiomyolipoma proved through fine needle aspiration biopsy, (3) patients with good compliance, and (4) not a hepatitis
virus carrier.
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Introduction
Hepatic angiomyolipoma (AML) is a rare mesenchymal
tumor of the liver composed of smooth muscle cells,
adipose tissue, and proliferating blood vessels. Since its
first description by Ishak in 1976, approximately 200 cases
have been reported in the English literature.
1 This type of
tumor is usually seen in kidneys associated with tuberous
sclerosis.
2 Definite pathologic diagnosis is made by
identification of the three different components and HMB-
45 positive staining.
3
In the past, this tumor has been considered an entirely
benign and slow-growing lesion without the possibility of
malignant transformation. Therefore, several authors have
suggested that this disease can be managed with conserva-
tive treatment.
4–7 However, since 2000, several reports
have revealed that this kind of tumor can be malignant with
evidence of recurrence.
8–10 Although the combination of
ultrasonography, computed tomography (CT), magnetic
resonance (MR) imaging, and angiography increases the
accuracy in diagnosis of hepatic AML, the correct
preoperative diagnostic rate of imaging studies has been
reported to be less than 50%.
6,10–14 Even the postoperative
pathologic diagnosis has been easily mistaken as hepato-
cellular carcinoma (HCC).
14,15 Many patients have been
treated with surgical resection of the tumor. Therefore, the
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The purpose of this study is to retrospectively review the
clinical, imaging, and pathological features of patients with
hepatic AML treated at our hospital and to summarize our
experience in the diagnosis and treatment of this disease.
We also review the literature to highlight the important
questions concerning hepatic AML: (1) Is hepatic AML a
pure benign tumor? (2) What is the natural course of this
tumor? Does the tumor size enlarge frequently during
observation? (3) What difficulties exist in preoperative
diagnosis with imaging studies and fine needle aspiration
biopsy (FNAB)? (4) Is it proper for a hepatitis-carrier
patient with hepatic AML to be treated with conservative
management? (5) What are the criteria for patients with
hepatic AML to be treated with surgical resection or
conservative management?
Materials and Methods
The clinical, imaging, and pathological features of 10
patients with hepatic AML treated at the authors’ institute
were retrospectively reviewed. The follow-up information
was obtained in each case. All tumor tissue was paraffin-
embedded for routine hematoxylin and eosin (H&E)
staining. Immunohistochemical assays were performed
using a three-step indirect peroxidase complex technique
with the following antibodies: HMB-45 (DAKO, dilution
1:40), actin (DAKO, dilution 1:50), S-100 (DAKO, dilution
1:800), cytokeratin (Biogenix, dilution 1:80), vimentin
(DAKO, dilution 1:50), and c-kit (MBL, dilution 1:200).
Results
Patients and Clinical Data
Ten patients with hepatic angiomyolipoma were diagnosed
at National Taiwan University Hospital from July 1995 to
June 2004. There was marked female predominance (9/10).
The median age was 44 years old with a range from 34 to
64 years. Most patients (60%) presented no symptoms and
were detected incidentally by health check-ups or during
medical exams for other diseases. Four of 10 patients had
symptoms caused by the space-occupying effect of the
tumors such as abdominal pain, abdominal fullness, and
palpable mass, or other nonspecific symptoms such as
fever, general malaise, or body weight loss (Tables 1 and
2). None of them had a history of renal AML or tuberous
sclerosis. Two patients were hepatitis B-virus (HBV)
carriers. The plasma levels of α-FP and CEA were within
normal limits in all patients.
Imaging Studies
Based on the combined imaging studies of abdominal
ultrasonography, CT, MR imaging, and angiography, the
diagnostic accuracy of hepatic AML in this series was only
20% (Table 1). Other preoperative imaging impressions
included hepatocellular carcinoma, angiosarcoma, heman-
gioma, and metastatic lesions.
Two other cases were diagnosed by fine needle aspira-
tion biopsy (FNAB). The accurate preoperative diagnostic
rate was 40% (4/10) after imaging studies and FNAB
(Table 1).
Pathologic Study
All 10 patients had a single tumor. Five tumors were in the
right lobe of the liver and four were in the left lobe. One
tumor was located in the caudate lobe. Most tumor sizes
were larger than 5 cm (70%). The median tumor size was
10.5 cm, ranging from 2.5 cm to 20 cm (Tables 1 and 2).
Gross pathology identified all tumors as a well-circum-
scribed, nonencapsulated tumor masses consisting of soft to
elastic tissue. The cut surface in tumors varied from yellow
to dark brown.
Table 1 Clinical Presentation of Hepatic Angiomyolipoma
Clinical Feature No. of Patients
Age 34–64 years (median 44 years)
Gender (female: male) 9:1
Symptoms
No symptom 6
Abdominal pain 2
Abdominal fullness 2
Palpable mass 1
Body weight loss 2
Malaise 1
Fever 2
Tumor location
Right lobe 5
Left lobe 4
Caudate 1
Tumor size (cm)
<5 3
5–10 1
>10 6
Preoperative diagnosis
Angiomyolipoma 4(40%)
Based on radiological images 2
Based on tumor biopsy 2
Hepatocellular carcinoma 3(30%)
Angiosarcoma 1(10%)
Hemangioma 1(10%)
Metastasis 1(10%)
Associated liver disease
HBV carrier 2
J Gastrointest Surg (2007) 11:452–457 453Histopathologic studies of these 10 tumors showed a
picture of hepatic angiomyolipoma composed of myoid and
vascular components with a variant content of fatty tissue.
Hematopoiesis was noted in two cases. Immunohistochem-
ical studies were performed in all patients except one (case
5). Most tumors were found positive for HMB-45 (10/10),
SMA (4/9), S-100 (7/9), Vimentin (6/9), but negative for
cytokeratin (0/9). Only three tumors were found positive for
c-kit (Table 3).
Treatment and Follow-up
One patient (case 5) was confirmed with AML through fine
needle aspiration biopsy. Nonoperative management with
close follow-up was performed. However, this patient was
lost after 6 months of follow-up. The other nine patients
underwent hepatectomy with tumor resection. These nine
patients, except for one patient (case 3), had no postoper-
ative complications or disease recurrence, and were
regularly followed up at our outpatient department, fol-
low-up ranging from 32 to 109 months (Table 2). The very
unusual patient (case 3) was a 37-year-old woman with a
13×9×9 cm, large tumor at the left lobe of the liver,
receiving extended left lobectomy (Fig. 1a,b). Pathology
revealed a picture of hepatic AML (Fig. 2a,b).
Unfortunately, 6 months later, ultrasonography showed
recurrent hepatic lesions at the right lobe of the liver
(Fig. 1c). MRI also confirmed a large tumor in the caudate
lobe and numerous smaller nodules in the right lobe of the
liver. Angiography also revealed multiple tumor stains
(Fig. 1d). Fine needle aspiration biopsy was performed. The
biopsy specimen was immunoreactive to HMB-45 antibody
(Fig. 2c,d). The clinical and histologic picture demonstrated
recurrent malignant hepatic angiomyolipoma. At the 11th
postoperative month, chest CT scans revealed multiple
metastatic nodules. Three months later, the woman died due
to hepatic failure and renal failure.
Discussion
In the past, hepatic AML has been considered as a “benign”
mesenchymal tumor. However, in 2000, Dalle reported the
first case of malignant hepatic AML with vascular invasion
Table 3 Immunohistochemical Study
Case HMB-
45
Actin S-100 Cytokeratin Vimentin c-kit
1+ +− ++ −− +
2+ ++ + + − ++
3+ +− ++ − + −
4+ ++ + −− + −
5+ +
6+ ++ + +− + −
7+ +− ++ − + −
8+ +−−− + −
9+ +− ++ −− −
10 ++ + + − ++
++: strongly staining, >30% positivity; +: weakly staining, 10∼30%
positivity; − no staining, or <10% positivity
Table 2 Clinical Profile of Patients with Hepatic Angiomyolipoma
Case Sex/
Age
Tumor Size
(cm)/lobe
Symtoms/Signs Incidental Finding Treatment Outcome/F/U Months
1 F/34 18/R Nil H/C Atypical
hepatectomy
Well/39 mon
2 F/34 10/R Epigastralgia Right lobectomy Well/59 mon
3 F/37 13/L Palpable mass, abdominal
fullness, BW loss, fever
Extended left
lobectomy
Dead/14 mon recurrent,
liver and lung mets
4 F/40 20/R Epigastralgia Right lobectomy Well/109 mon
5 F/42 7/R Nil H/C FNAB and F/U Lost F/U/6mon
6 F/46 11/L Abdominal fullness, malaise,
BW loss, fever
Left lateral
segmentectomy
Well/40 mon
7 F/49 15/R Nil Exam of appendicitis S56
segmentectomy
Well/37 mon
8 F/51 3/C Nil H/C Caudate
lobectomy
Well/40 mon
9 F/53 2.5/L Nil F/U echo due to
colon cancer s/p
Left lateral
segmentectomy
Well/33 mon
10 M/64 4/L Nil H/C Left lobectomy Well/32mon
H/C=health check-up, BW=body weight, F/U=follow-up, FNAB=fine needle aspiration biopsy, mon=month, mets=metastasis, s/p=
postoperation
454 J Gastrointest Surg (2007) 11:452–457and recurrence with multiple liver metastases and suspected
portal vein thrombosis 5 months after primary tumor
resection.
8 Another two cases have been reported with
hepatic recurrence after operation. One case was a 16-year-
old girl with hepatic AML, receiving left lobectomy, with
late recurrence noted 6 years after operation.
9 The other one
was in the Flemming’s report. Recurrent hepatic tumors
were noted 3 years after operation.
10 Flemming also
suggested that a proliferation index exceeding 3% and
multicentric growth indicate a propensity for recurrence.
In this study, we reported a 37-year-old woman with left
hepatic AML. A recurrent hepatic mass was noted 6 months
after tumor resection, and multiple lung metastases were
noted later. The patient died 14 months after diagnosis. To
our knowledge, this case is the fourth reported case of
recurrence in the literature, and the tumor in this case be-
haved as the most malignant one.
8–10 Therefore, hepatic
AML should not be considered as an entirely benign tumor;
at least, it has malignant transformation potential. Accord-
ingly, conservative treatment should be performed carefully,
especially for patients with poor compliance, who are
unable to undergo a strict follow-up regimen.
There were few reports concerning the growth velocity
of hepatic AML in long-term follow-up. In one retrospec-
tive study of 26 patients, there were six patients who were
followed up for more than 1 year and finally decided to
receive operation because of the enlargement of the lesions.
In that study, the tumor size of one patient increased from 4
to 10 cm during the 5-year follow-up. Another patient had a
tumor increasing from 1.5 to 5 cm in 13 years follow-up.
13
Figure 1 A 37-year-old woman (case 3) presented with fever and
palpable abdominal mass. (a) The axial view of contrast-enhanced CT
scans on portal venous phase shows a huge hepatic tumor at the left
hepatic lobe with heterogeneous enhancement. Notice the engorged
vessels within the tumor are vividly identified (arrow). (b) The MR
coronal Tru FISP, fast imaging with steady-state precession. (TR/TE/
FA=4.3/2.1/72°) shows engorged vessels in the tumor. The right portal
vein (arrow) is displaced by the tumor. (c) After 6 months of extended
left lobectomy, the abdominal ultrasonography reveals a huge recurrent
tumor (arrows) in the previous location of left hepatic lobe, and
numerous smaller tumors in the right lobe. (d) Celiac angiography also
demonstrates the recurrent huge tumor and other multiple smaller ones
in the right lobe of liver. Note the early drainage vein (arrow).
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size enlarged from 8 to 14.4 cm over a 3-year follow-up
period.
16 Irie also reported that a 40-year-old woman had
hepatic AML with tumor size increasing in size from 4 cm
to 7 cm during a 14-month follow-up period.
16
Although hepatic AML seems slow-growing, the prob-
ability of tumor enlargement and hence an induced mass-
compression effect is not uncommon in the long-term
follow-up period. In the present series, the median age of
patients was 44 years old, and 70% of patients were below
50 years. If all of these patients had received nonoperative
management, the mass effect of tumor enlargement might
have been presented during a long-term follow-up period,
especially in younger patient groups with longer remaining
years of life. Moreover, the difficulties and complications of
operation at later years would increase when the tumor
enlarges, especially for those patients with an original larger
tumor (>5 cm).
Similar to the patients presented in this series, most
patients with hepatic AML are not symptomatic.
12–14
Usually, these patients are diagnosed during health check-
ups. Most symptoms are mass-compression effects includ-
ing upper abdominal pain, abdominal fullness, and palpable
mass. There are also some vague symptoms such as body
weight loss, general malaise, and fever. In one review
article with a collection of 52 patients, the incidence of
symptoms or signs dramatically increased when tumor size
was larger than 5 cm.
11 Twenty-one percent (4/19) of
patients with a tumor smaller than 5 cm present symptoms/
signs; however, the incidence increases to 64% (7/11) when
tumor size is between 5 and 10 cm. The incidence increases
to 89% when tumor size is larger than 10 cm. In our series,
40% (4/10) of patients were symptomatic, and all four of
these patients had a tumor larger than 10 cm. Accordingly,
we suggested that patients with tumor larger than 5 cm
should receive tumor resection, because most patients in
this group were predisposed toward being symptomatic.
The typical findings in imaging studies of hepatic AML
are as follows: (1) heterogeneously hyperechoic mass in US,
(2) heterogeneously low density with low attenuation value
(less than −20 HU) in plain CT, (3) high intensity on T1 and
T2 weighted MRI, and (4) hypervascularity and tumor stain
on angiography.
12 Although a combination of US, CT,
MRI, and angiography is able to increase the accuracy in
preoperative diagnosis, hepatic AML usually shows various
patterns in imaging studies. The differences in imaging
studies occur because the relative proportions of vessels,
muscles, and fatty tissue vary widely from one tumor to
another. Consequently, hepatic AML is sometimes difficult
to diagnose based on imaging studies.
17 Therefore, fine
needle aspiration biopsy has been reported to be useful in
the preoperative diagnosis of this tumor.
4,5,17,18
However, more attention should be paid to the tumor’s
various morphologic appearances when minute samples
are interpreted. With the combined tools of imaging
studies and FNAB, the preoperative diagnostic accuracy
has been smaller than 32% (ranging from 0 to 32%) in
larger series.
6,10–15 In a collaborative study reported by
Figure 2 Microscopic appear-
ance of the hepatic angiomyoli-
poma in case 3. (a) The primary
tumor is composed of polygonal
to spindle cells arranged in solid
sheets or trabecular pattern with
endothelial lining. Some of the
tumor cells have eosinophilic
cytoplasm, and some have large
fat vacuoles. Some of the nuclei
are bizarre, and some have large
eosinophilic nucleoli (H&E
stain, original magnifica-
tion×100). (b) The tumor cells
are strongly immunoreactive for
HMB-45 (original magnifica-
tion×100). Recurrent tumor was
noted 6 months later, and the
patient received fine needle as-
piration biopsy. (c) Microscopi-
cally, it shows tumor cells with
clear to ample eosinophilic cy-
toplasm arranged in trabecular
pattern (H&E stain, original
magnification×40). (d) Immu-
nohistochemical staining shows
the tumor cells are also positive
for HMB-45 (original magnifi-
cation×200).
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centers, 50% were primarily misdiagnosed as carcinoma or
sarcoma, either by imaging studies or by needle biopsy.
15 In
Flemming’s series, only one preoperative case was diag-
nosed correctly.
10 In the present series, only four preoper-
ative cases (40%) were correctly diagnosed by combined
imaging studies and FNAB.
Definite pathologic diagnosis of this tumor is usually
made by identification of the three different components of
smooth muscle cells, adipose tissue, and blood vessels.
HMB-45 positive staining of myoid cells has been used as a
pathologic characteristic of hepatic AML.
3,19 Because of
the rarity and pleomorphism of the histological features of
hepatic AML, histologic diagnosis may be difficult,
especially with needle biopsy. Many features in AML can
mislead the unwary pathologist to a diagnosis of hepatocel-
lular carcinoma: polygonal cells in trabecular arrangement,
peliosis, nuclear pleomorphism, prominent eosinophilic
nucleoli, deficient reticulin framework, presence of glyco-
gen, eosinophilic globules, and tumor necrosis.
14 In Zhong’s
series of 2000, none of the 14 cases were correctly
diagnosed before operation. Furthermore, five cases were
misdiagnosed as hepatocellular carcinoma or sarcoma by
pathologists, even after operation. Therefore, we should be
cautious when using FNAB as a diagnostic tool.
In an endemic area of hepatocellular carcinoma such as
Taiwan,
20 conservative management is risky because cases
of fat-rich minute hepatocellular carcinoma will make the
differential diagnosis more difficult. Furthermore, Chang
reported one case with hepatic AML and concomitant hepa-
tocellular carcinoma.
21 In this series, two patients were
carriers of hepatitis B virus with a high risk for hepatoma
formation. Not only would these hepatitis-carrier patients
bear more risk, but physicians would also bear more risk and
psychological pressure during a long-term follow-up period
if conservative management were adopted.
Because of the small patient number, we could not get
definitely conclusive management suggestions solely from
the results of this retrospective study. But a combination of
our experience and a review of the literature, we suggest all
symptomatic patients should receive surgical resection for
hepatic angiomyolipoma. Conservative management with
close follow-up is suggested in patients with asymptomatic
tumors and meet the following criteria: (1) tumor size
smaller than 5 cm, (2) angiomyolipoma proved through fine
needle aspiration biopsy, (3) patients with good compliance,
and (4) not a hepatitis-virus carrier.
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